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Abstract
Background: Mycetoma is a chronic infectious disease of tropical and subtropical countries. It is produced by true fungi and
actinobacteria. In Me ´xico, Nocardia brasiliensis is the main causative agent of mycetoma, producing about 86% of the cases;
the gold standard for the therapy of mycetoma by N. brasiliensis is the use of sulfonamides which give a 70% cure rate. The
addition of amikacin to this regime increases to 95% the cure rate; however, the patients have to be monitored for
creatinine clearance and audiometry studies because of the potential development of side effects. Because of that it is
important to search for new active compounds. In the present work, we evaluated the in vivo effect of DA-7867, an
experimental oxazolidinone, on the development of experimental mycetomas by N. brasiliensis in BALB/c mice.
Methodology/Principal Findings: In order to determine the optimal dose utilized to apply to the animals, we first
determined by HPLC the plasma levels using several concentrations of the compounds. Based on these results, we used 10
and 25 mg/kg subcutaneously every 24 hr; DA-7867 was also supplied in the drinking water at a calculated dose of 25 mg/
kg. As a control we utilized linezolid at 25 mg/kg, a compound active in murine and human infections, three times a day.
The mice were infected in the right footpad with a young culture of N. brasiliensis HUJEG-1, and one week later we started
the application of the antimicrobials for six more weeks. After that we compared the development of lesions in the groups
injected with saline solution or with the antimicrobials; the results were analyzed by the variance ANOVA test. DA-7867 was
able to reduce the production of lesions at 25 mg/kg, when given either subcutaneously or in the drinking water.
Conclusions/Significance: The experimental oxazolidinone DA-7867 is active in vivo against N. brasiliensis, which opens the
possibility of using this drug once it is accepted for human application. Since oxazolidinones seem to be active against a
wide spectrum of actinobacteria, it is possible they could be used in human cases of mycetoma by other actinomycetales,
such as Streptomyces somaliensis, highly prevalent in Sudan, or Actinomadura madurae and A. pelletieri, which are commonly
observed in Africa and India.
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Introduction
Mycetoma is a multi-etiological subcutaneous infection caused
by true fungi and aerobic actinomycetes observed in many tropical
and sub-tropical countries. In Mexico, 98% of the total cases are
produced by actinomycetes and about 86% are produced by N.
brasiliensis [1]. Many antimicrobials have been used in the therapy
of actinomycetoma, including sulfonamides (DDS, sulfamethox-
ypyridazine, and sulfadoxine), streptomycin in combination with
dapsone or with trimethoprim-sulfamethoxazole (SXT), minocy-
cline, imipenem, amoxicillin-calvulanic acid, etc. [2]. The highest
cure rates (70%) have been obtained with the use of sulfameth-
oxazole-trimethoprim (SXT). In our dermatology clinic we have
added amikacin to the SXT combination to treat severe cases of
mycetoma or those cases involving subjacent organs, obtaining a
cure rate of about 95% in a series of 52 patients [3]. However, in
some cases, the use of these antimicrobials carries the risk of side
effects or bacterial resistance.
Oxazolidinones are recently developed antimicrobials that
inhibit protein synthesis in a site not targeted by other
antimicrobials [4]. Resistance by mutations or the presence of a
resistance determinant has rarely been reported. The first of these
compounds to be approved by the Food and Drug Administration
(FDA), linezolid, has been observed to be active in vitro against
several gram-positive actinobacteria including Nocardia, Actinoma-
dura, and Mycobacterium tuberculosis [5,6,7]. Linezolid has been
successfully tested by us in an experimental model of infection with
N. brasiliensis in BALB/c mice, and this activity has been confirmed
in human infections [8,9]. However, in long term applications,
linezolid produces side effects, such as myelosuppression and
www.plosntds.org 1 September 2008 | Volume 2 | Issue 9 | e289peripheral neuropathy [10]. Therefore it is important to look for
more powerful and less toxic oxazolidinones. Recently, an
experimental oxazolidinone, DA-7867 ((S)-[N-3-(4-[2-(1-methyl-
5-tetrazolyl)-pyridin-5-yl]-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide) has been observed to be highly active in vitro
against N. brasiliensis isolates [5], even at much lower concentra-
tions than linezolid, which makes this drug an excellent candidate
to be tested in vivo.
In the present work, we used an animal model to study the in
vivo activity of this experimental compound, and compared its
effectiveness with that of linezolid.
Methods
Microorganisms
For the animal assays we utilized Nocardia brasiliensis HUJEG-1
which has been utilized in previous studies [8,11,12]. The MIC
values of this strain are 0.03 mg/ml for DA-7867, and 0.12 mg/ml
for linezolid. The strain was grown on Sabouraud dextrose agar
for 7 to 10 days and a suspension in 20% skim milk of each was
made. These bacterial suspensions constituted our stock cultures
that were kept at 270uC in cryovials until use.
Determination of plasma levels of the antimicrobials
Several doses of each compound linezolid or DA-7867 were used
to determine their plasma concentrations in BALB/c mice.
Linezolid was used at 10 mg/kg, 25 mg/kg and 50 mg/kg; DA-
7867 at 10 mg/kg and 25 mg/kg. Eight-to-twelve week-old female
BALB/c mice were injected subcutaneously with the antimicrobi-
als. For each dose tested, 27 mice were utilized; 24 were injected
with the selected dose and 3 mice were not injected to represent
time 0. Next, 500 ml blood samples were taken from the
infraorbitary sinus of each mouse, which previously had undergone
general anesthesia with ethylic ether. The samples were taken from
groups of 3 mice each at the following time intervals: 0 min,
20 min, 40 min, 1 hr, 2 h, 4 h, 6 h, 8 h and 10 h.
After sample collection, the plastic tubes containing the blood
were centrifuged and the plasma separated and frozen at 270uC.
Plasma concentrations were determined by using by using a
previously validated HPLC (High Performance Liquid Chromatog-
raphy) method as follows [13]. The serum protein was precipitated
by combining 50 mLo fs a m p l ew i t h1 5 0ml of acetonitrile. The
mixture was vortexed for 10 sec and centrifuged for 5 min at
53046g, and the supernatant was filtered through 0.45 mmN y l o n
filters (Waters). Filtrates were received into 150 mL inserts for
chromatographic analysis. The chromatographic separation of
antimicrobials was achieved using a Waters 2690 Alliance liquid
chromatograph with diode array detector 996 (DAD) and
fluorescence detector 474. An Atlantis dC18 column 150 mm6
4.6 mm I.D., with 5 mm particle size (Waters) was used. Column
temperature was maintained at 30uC. Samples were eluted with a
mobile phase consisting of 0.1% trichloroacetic acid (solvent A) and
acetonitrile (solvent B); a gradient program was utilized for the
elution.In thecaseofDA-7867,inordertoreduce theretentiontime
of this analyte, this program was modified with an increase in the
initial proportion of acetonitrile. The flow rate of the mobile phase
was 1.0 mL/min and the injection volume was 10 mL. The DAD
wavelength was set at 254 nm for linezolid; for DA-7867 the
fluorescenceintensitiesweremeasuredatanexcitationwavelengthof
292 nm and an emission wavelength of 408 nm.
Inoculum preparation for the animal assay
N. brasiliensis HUJEG-1 was cultured in Sabouraud agar for 1
week, and then cultured in Brain-Heart-Infusion broth at a
temperature of 37uC in a shaker at 110 RPM for 72 hrs. The
bacterial mass was then separated by centrifugation, and washed
4-times with saline solution. After grinding in a Potter-Evelham
device the suspension was left to sediment and the bacterial mass
was washed one more time with saline solution and adjusted to
20 mg (wet weight) of N. brasiliensis per 50 mL of saline solution.
Experimental infection
Eight-to-twelve week old female BALB/c mice were inoculated
with 20 mg of Nocardia brasiliensis in the right hind foot-pad. Seven
days later the therapeutic assay was started.
Therapeutic assays
Groups of 15 mice each were used. One group was injected
subcutaneously in the back with 0.1 ml pyrogen-free saline
solution; the rest were treated with DA-7867 at a dose of
10 mg/kg and 25 mg/kg daily, and linezolid at a dose of 25 mg/
kg three times a day. The drugs were administered subcutaneously
on the back of each mouse during a four week period.
Since itis morecomfortablefor the patient to take the compounds
orally, we studied this possibility by giving DA-7867 in this way.
However, since it was a long term experiment (the antimicrobial had
to be given five times a week during four weeks ) and to avoid a
possible esophageal ripping due to the insertion of the oral cateter,
we decided to give it in the drinking water. DA-7867 was suspended
in 10% hydroxypropylcellulose and given in the drinking water at a
dose of 25 mg/kg. The amount of compound was calculated
according to the amount of water drank during the day per each
animal. Since the amount of antimicrobial taken by the animals was
not completely controlled we determined the levels in the plasma of
the animals by the HPLC method described above at 0, 3, 6, 9, and
12 h after they started to drink a new bottle.
Evaluation of the therapeutic assays
The lesions in the foot pad were scored based on the degree of
extension as published previously [8], with scores ranging from 0 for
those presenting absolutely no lesions or inflammation to 4+ for the
Author Summary
Actinomycetoma is an infectious disease of tropical and
subtropical regions produced by actinobacteria of the
genera Nocardia, Streptomyces,a n dActinomadura. Thera-
peutic alternatives are scarce and include trimethoprim-
sulfamethoxazole, diaminodiphenylsulfone, amoxicillin-clav-
ulanate, imipenem, and amikacin. Oxazolidinones are a new
class of antimicrobials with a completely different cellular
target; the first compound in the market, linezolid, was
introduced in the year 2000. It is active against many species
of Nocardia and other aerobic actinomycetes; however, the
long-term application in human subjects produces side
effects including peripheral neuropathy and mielossupres-
sion.Therefore,itisimportanttoscreenotheroxazolidinones
with higher activity and less toxicity. In the present work, we
tested DA-7867, a new oxazolidinone, in an experimental
mouse model. The drug is active in vivo and decreases the
production of lesions using only one dose a day in contrast
to linezolid, which needs to be injected three times a day.
Although it was tested on N. brasiliensis, it can possibly be
active (once it is accepted for its use in humans) against
Actinomadura spp and Streptomyces spp, which are frequent-
ly found in places of Africa and India where actinomycetoma
is also an important consult in dermatology.
Experimental Therapy of Actinomycetoma
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bones. Differences among the therapeutic group were analyzed with
an ANOVA test and confirmed with the Dunnet test.
The study was approved by the Comite ´ Local de Investigacio ´n
en Salud No. 1908, Centro de Investigacio ´n Biome ´dica del
Noreste, IMSS, and the animal handling was done according to
our institutions’ guidelines.
Results
Antimicrobial plasma levels
The concentrations of linezolid in plasma of BALB/c mice has
been published before [12]. At 25 mg/kg it keeps concentrations
above the MIC value (0.12 mg/ml) for more than 4 hr, with a Cmax
of50 mg/ml.Ontheotherhand,DA-7867maintainsconcentrations
over the MIC (0.03 mg/ml) even at 10 h at 10 and 25 mg/kg, with a
Cmax of about 200 mg/ml at 25 mg/kg (Fig 1). The plasma levels
found in rats are different as reported by Bae et al [14].
When given in the drinking water plasma concentrations of the
compound were over the MIC the 12 h, with a Cmax of 2.8 mg/ml
at 3 h after start drinking (Fig 1).
Experimental model of actinomycetoma
This actinomycetoma model has been described in a former
publications [8,11,12]. In brief, inoculation of 20 mg wet weight of
N. brasiliensis culture, produced a highly inflammatory response 5
days post inoculation. After this point footpad thickness decreases
and at the end of 4 weeks, there is the installation development of
real mycetoma lesions. If left for months, giant mycetoma lesions
develop and remain localized. To interpret the therapeutic effect
of the various compounds, we decided to treat the animals for 4
weeks by which time the lesions are installed, and they have
reached the equivalent size of a human mycetoma.
Therapeutic effect of DA-7867
In Fig. 2, we observe the effect of DA-7867 at 10 mg/kg every
24 hr. At this first dose, DA-7867 had no effect on the evolution of
the mycetoma lesions, and this therapeutic group was undistinguish-
ablefrom the control. When increasing the dose to 25 mg/kg a clear
effect on the production of mycetomatous lesions was observed
(Fig 3). When the results were analyzed with the one-way ANOVA
test, only the treatments with DA-7867 at 25 mg/kg and linezolid
were statistically significant (p=0.002). Equal results were obtained
when analyzing the mean values with the Dunnet test.
In the group of animals were DA-7867 was given in the drinking
water at 25 mg/kg (Fig 3), we observed a comparable effect to that
obtained when the antimicrobial was applied subcutaneously at
the same concentration, observing also a significant statistical
difference with the ANOVA (p=0.002) and Dunnet tests when
comparing with the group receiving saline.
Discussion
Currently there are not many alternatives for the therapy of
actinomycetoma by N. brasiliensis. The most common antimicrobials
utilized, SXT and the combination SXT-amikacin are not 100%
effective, and it is known that these compounds can induce side
effects such as Stevens-Johnson syndrome, hypacusia, and nephro-
toxicity. Since antimicrobials have to be taken for long periods of
time, adherence to treatment is very important to avoid the
appearance of resistance. However most of the patients are poor, ill-
educated and live in rural areas far from hospital and when they
come back to the consult it is because of remission of the disease.
Therefore, more potent and less toxic compounds are needed.
Quinolones such as gatifloxacin, moxifloxacin and garenoxacin,
as well as linezolid, a compound of the class of the oxazolidinones,
are among the new antimicrobials tested against N. brasiliensis which
are active in vitro against the 100% of the isolates tested [5,8]. Of
them only gatifloxacin and linezolid have been tested in the mouse
model of actinomycetoma by N. brasiliensis with positive results
[8,12]; unfortunately, gatifloxacin has been withdrawn from the
market because of the report of the production of disglycemia [15].
Its return to the pharmaceutical shelves will depend very much on
the results of the clinical trials with patients with tuberculosis, where
it seems to be as active as ethambutol [16].
On the other hand, linezolid has been used to treat successfully
some cases of subcutaneous nocardiosis; however after several
months of use neurological and haematological side effects were
observed in some patients [9]. In our experience, we treated a
patient presenting a case of subcutaneous nocardiosis of the leg,
with dissemination to the abdomen and formation of large retro-
Figure 1. Mouse plasma levels of DA-7867 given subcutaneously (left) and in the drinking water (right). DA-7867 was given s.c. at 10 (N)
and 25 (#) mg/kg. In the right picture we show the levels produced after giving the compound at a dose of 25 mg/kg in the drinking water. Each
point represents the mean of three animals.
doi:10.1371/journal.pntd.0000289.g001
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www.plosntds.org 3 September 2008 | Volume 2 | Issue 9 | e289Figure 2. Effect of the application of saline solution, linezolid, or DA-7867 (at 10 mg/kg per day) on the development of lesions by
N. brasiliensis on the mouse footpad. Statistically significant (p,0.005) differences from the control animals were observed only in the group
treated with linezolid.
doi:10.1371/journal.pntd.0000289.g002
Figure 3. Effect of the application of DA-7867 at 25 mg/kg, subcutaneously or in the drinking water, in the development of
experimental lesions by N. brasiliensis. Differences in the number of animals were considered for the variance statistical analysis. In both cases
statistically significant differences with respect to the control were observed (p=0.002 in both cases).
doi:10.1371/journal.pntd.0000289.g003
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resistant to amikacin, SXT, and amoxicillin-clavulanic acid; the
patient was successfully treated with 600 mg daily of linezolid for 3
months without the production of side effects. This encouraged us
to look for new drugs for resistant cases of actinomycetoma. In
previous in vitro studies we observed that Nocardia spp and
Actinomadura madurae isolates are susceptible to antimicrobials not
previously used in patients with mycetoma, including new
oxazolidinones [4]. One of them DA-7867, was observed to be
even more active than linezolid and amikacin. These in vitro
results made them excellent candidates for in vivo experimenta-
tion.
In a previous work, we have observed that plasma levels of
linezolid in BALB/c mice at a dose of 50 mg/kg remains for about
4 hr over the MIC value, with a Cmax of of 70 mg/ml [12]. DA-
7867 reaches much higher concentrations in plasma with a Cmax
of 200 mg/ml at 25 mg/kg, maintaining levels above the MIC
(0.03 mg/ml) for more than 10 hr. Because of the high levels
observed in plasma we decided to use it in a low dose (10 mg/kg),
and only once a day; however under this conditions we did not
observe any clinical differences compared to the control. When
using a higher dose (25 mg/kg, daily), we could observe a
therapeutic effect, comparable to that of linezolid applied three
times daily. This is perhaps due to the exquisite susceptibility of N.
brasiliensis to this drug (MIC=0.03 mg/ml), compared to 0.12 mg/
ml of linezolid. Importantly, when it was given in the drinking
water at a calculated dose of 25 mg/kg, even if the amount of
compound taken was not controlled we observe a comparable
effect to the drug given subcutaneously. It is important to remark
that appearance of the animals was excellent, since we did not had
to manipulate them at all, compared to the groups of animals that
had to be injected subcutaneously several times a day. These
results open the possibility to give DA-7867 orally instead than
subcutaneously, which is more comfortable for the patient. This is
important since adherence to the treatment is essential for
successful long term therapeutic schemes.
One of the most important factors which determine the use of
experimental drugs in humans is their poor solubility in water.
Recently, Dong-A-Pharm has developed a pro-drug DA-7218, a
new oxazolidinone, which in the body is dephosphorylated to the
active compound DA-7257 [14]. In contrast to linezolid and DA-
7867, DA-7218 is highly soluble in water (greater than 150 mg/ml
at pH 7.0) and it is quite active against N. brasiliensis in vivo, even
at 5 mg/kg. It is important to mention that therapy with DA-7867
and DA-7218 produced animals with no lesions or slight
inflammation (scored in Fig. 3 as neg or +/2); experimental
therapy with other compounds such as linezolid, or amoxicillin-
clavulanate only produced decrease of the lesions, but without
curing the infection completely [8]. It is possible that this new
oxazolidinones have a more potent bactericidal effect, which will
be beneficial for the patients, although we still will have to wait to
test them until they are approved for human use.
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